130 related articles for article (PubMed ID: 38291715)
1. Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.
Toyoda H; Tada T; Uojima H; Nozaki A; Chuma M; Takaguchi K; Hiraoka A; Abe H; Itobayashi E; Matsuura K; Atsukawa M; Watanabe T; Shimada N; Nakamuta M; Kojima M; Tsuji K; Mikami S; Ishikawa T; Yasuda S; Tsutsui A; Arai T; Kumada T; Tanaka Y; Tanaka J; Chayama K
J Gastroenterol Hepatol; 2024 May; 39(5):949-954. PubMed ID: 38291715
[TBL] [Abstract][Full Text] [Related]
2. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T
J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094
[TBL] [Abstract][Full Text] [Related]
3. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.
Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T
J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762
[TBL] [Abstract][Full Text] [Related]
4. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
5. Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Who Achieved Sustained Virologic Response.
Toyoda H; Tada T; Yasuda S; Mizuno K; Ito T; Kumada T
Clin Infect Dis; 2020 Mar; 70(6):1208-1214. PubMed ID: 31056696
[TBL] [Abstract][Full Text] [Related]
6. PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication.
Miki D; Akita T; Kurisu A; Kawaoka T; Nakajima T; Hige S; Karino Y; Toyoda H; Kumada T; Tsuge M; Hiramatsu A; Imamura M; Aikata H; Hayes CN; Honda K; Seike M; Akuta N; Kobayashi M; Kumada H; Tanaka J; Chayama K
J Gastroenterol; 2020 Dec; 55(12):1162-1170. PubMed ID: 33057914
[TBL] [Abstract][Full Text] [Related]
7. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095
[TBL] [Abstract][Full Text] [Related]
8. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance.
Tong MJ; Theodoro CF; Salvo RT
J Dig Dis; 2018 Jul; 19(7):411-420. PubMed ID: 29889353
[TBL] [Abstract][Full Text] [Related]
9. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.
Alonso López S; Manzano ML; Gea F; Gutiérrez ML; Ahumada AM; Devesa MJ; Olveira A; Polo BA; Márquez L; Fernández I; Cobo JCR; Rayón L; Riado D; Izquierdo S; Usón C; Real Y; Rincón D; Fernández-Rodríguez CM; Bañares R
Hepatology; 2020 Dec; 72(6):1924-1934. PubMed ID: 33022803
[TBL] [Abstract][Full Text] [Related]
10. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
11. Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C.
Chun HS; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Lee CH; Lee YB; Cho EJ; Yu SJ; Kim YJ; Yoon JH; Lee JH; Kim SU
Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):378-385. PubMed ID: 32011388
[TBL] [Abstract][Full Text] [Related]
12. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection.
Toyoda H; Yasuda S; Shiota S; Sone Y; Maeda A; Kaneoka Y; Kumada T; Tanaka J
Aliment Pharmacol Ther; 2021 Jun; 53(12):1309-1316. PubMed ID: 33896023
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication.
Vutien P; Kim NJ; Moon AM; Johnson KM; Berry K; Green PK; Ioannou GN
Aliment Pharmacol Ther; 2024 Feb; 59(3):361-371. PubMed ID: 37955206
[TBL] [Abstract][Full Text] [Related]
15. Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals.
Tamaki N; Higuchi M; Kurosaki M; Kirino S; Osawa L; Watakabe K; Wang W; Okada M; Shimizu T; Takaura K; Takada H; Kaneko S; Yasui Y; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Enomoto N; Izumi N
J Viral Hepat; 2019 Jul; 26(7):893-899. PubMed ID: 30974045
[TBL] [Abstract][Full Text] [Related]
16. Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index.
Lee K; Sinn DH; Gwak GY; Cho HC; Jung SH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Gut Liver; 2016 Sep; 10(5):796-802. PubMed ID: 27114418
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Hepatocellular Carcinoma Development in Korean Patients after Hepatitis C Cure with Direct-Acting Antivirals.
Hong H; Choi WM; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Choi J
Gut Liver; 2024 Jan; 18(1):147-155. PubMed ID: 37076993
[TBL] [Abstract][Full Text] [Related]
18. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.
Kobayashi M; Suzuki F; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2017 Mar; 89(3):476-483. PubMed ID: 27531586
[TBL] [Abstract][Full Text] [Related]
19. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.
Ioannou GN; Beste LA; Green PK; Singal AG; Tapper EB; Waljee AK; Sterling RK; Feld JJ; Kaplan DE; Taddei TH; Berry K
Gastroenterology; 2019 Nov; 157(5):1264-1278.e4. PubMed ID: 31356807
[TBL] [Abstract][Full Text] [Related]
20. GES: A validated simple score to predict the risk of HCC in patients with HCV-GT4-associated advanced liver fibrosis after oral antivirals.
Shiha G; Waked I; Soliman R; Elbasiony M; Gomaa A; Mikhail NNH; Eslam M
Liver Int; 2020 Nov; 40(11):2828-2833. PubMed ID: 32946647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]